Rahul Bhargava, Director and Head of Hematology, Hematooncology, and Stem Cell Transplant at Fortis Health Care, shared a post on LinkedIn:
“Three days can change the direction of Acute Myeloid Leukaemia care.
This is not just about faster testing. It is about faster thinking, faster decisions, and faster access to precision haematology for patients with blood cancer.
A heartfelt thank you to the great physicians of our country, who continue to think only and only about the patient. By adopting advanced genomic technology with such speed and commitment, Indian haematologists are showing that precision medicine need not remain limited to a few global centres.
Rapid genomic testing allows us to understand the biology of AML early, choose the right treatment strategy, reduce avoidable toxicity, minimise complications, shorten hospital stay, and make treatment more affordable for families.
This is the real promise of precision haematology: right test, right time, right treatment, right outcome.
India is no longer just following global models. India is building a model of its own – practical, scalable, patient-centric, and ready for the world.
Now is the time to take India’s rapid genomic testing model across the globe.
Because in AML, every day matters. And sometimes, three days can change everything.”
Other articles featuring Rahul Bhargava on OncoDaily.